NASH disease is a growing public health crisis. 76%* of individuals with type 2 diabetes (T2D) and 90%** of obese adults have nonalcoholic fatty liver disease (NAFLD). Given NAFLD close association with T2D and obesity , the prevalence of both NAFLD and NASH is likely to continue to increase with and estimation of 30%*** of NASH patients developing liver fibrosis that can progress to Cirrhosis and to Hepatocellular Carcinoma.
Join the 2023 NASH Club, a series of 3 full educational CME accredited HCPs program and courses dedicated to all matters NAFLD-NASH.
You will learn from 12 EU top experts of a wide range of medical specialties: Hepatologists, Gastroenterologists, Diabetologists, Endocrinologists, and General practitioners. You can register for free once and attend the full series. By attending the full series, you will earn 3 CME credits.
>> Download the full program <<
Echosens gives institutional support to the event.
Register Now
FibroScan®
